Analytical Data
-
Gene name
CD11c
- Application
-
Alternative Names
ITGaX; CD11-C; ITG-AX; ITGA-X; Leu M5; Complement Component 3 Receptor 4 Subunit; CD11 antigen-like family member C; Leukocyte adhesion glycoprotein p150,95 alpha chain
-
Species
Human
-
Source
HEK293
-
Tag
N-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P20702
-
Expression Region
Gln143~Ser344
-
Molecular Weight
27&29kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Related Products
Protein Description
CD11c, a member of the integrin family, is primarily expressed on dendritic cells and plays a crucial role in the immune response by mediating cell adhesion and signaling pathways involved in the activation and maturation of these antigen-presenting cells. Understanding CD11c's function has significant implications for immunology and therapeutic interventions in various diseases, including autoimmune disorders, infections, and cancer. The study of recombinant CD11c proteins has garnered attention for its potential in developing vaccines and immunotherapies, as these proteins can be used to enhance antigen presentation and stimulate T-cell responses. Through genetic engineering techniques, researchers have been able to produce recombinant CD11c proteins for both basic research and clinical applications, providing insights into the molecular interactions that govern immune responses. These studies aim to unravel the complexities of the immune system and explore how manipulating CD11c activity could lead to novel treatment strategies to improve patient outcomes in various immunological conditions.
